Head-to-head evidence
HRX0701 vs SP2086
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
HRX0701
Developed by Jiangsu Hengrui Pharmaceuticals
NCT05415644 · Phase 1 · completed
This is a randomized, blinded, crossover comparison against the reference formulation, which is a sound design for its purpose, but it measures only drug levels in the blood rather than a diabetes outcome, and no results have been posted yet.
SP2086
Developed by Jiangsu Hengrui Pharmaceuticals
NCT01970033 · Phase 3 · status unknown
This is a large, randomized, quadruple-blind, placebo-controlled trial using the standard glycemic control measure for diabetes as its primary endpoint, but no results have been posted yet, so whether the drug lowered HbA1c more than placebo is unknown. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRX0701's landscape · SP2086's landscape